Epigenetic field cancerization in gastrointestinal cancers

Cancer Letters

Volumn 375, Issue 2, 2016, Pages 360-366

  Baba, Yoshifumi ^a   Ishimoto, Takatsugu ^a   Kurashige, Junji ^a   Iwatsuki, Masaaki ^a   Sakamoto, Yasuo ^a   Yoshida, Naoya ^a   Watanabe, Masayuki ^b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Cancerization; Epigenetic field defect; Gastrointestinal cancer; Long interspersed nucleotide element 1; Methylation

Indexed keywords

DNA;

CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL TISSUE; ESOPHAGUS CANCER; HEREDITY; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STOMACH CANCER; VISUAL FIELD DEFECT; GASTROINTESTINAL TUMOR; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

DNA METHYLATION; EPIGENESIS, GENETIC; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 84962599129     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.03.009     Document Type: Review

References (88)

1. Baba Y., Watanabe M., Baba H. Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg. Today 2013, 43(12):1355-1364.
2. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6(5):963-968.
3. Dakubo G.D., Jakupciak J.P., Birch-Machin M.A., Parr R.L. Clinical implications and utility of field cancerization. Cancer Cell Int 2007, 7:2.
4. Heaphy C.M., Griffith J.K., Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res. Treat 2009, 118(2):229-239.
5. Utsunomiya T., Shimada M., Morine Y., Tajima A., Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci 2014, 105(7):749-754.
6. Lee Y.C., Wang H.P., Wang C.P., Ko J.Y., Lee J.M., Chiu H.M., et al. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers. Cancer Prev. Res. (Phila) 2011, 4(12):1982-1992.
7. Di Domenico M., Santoro A., Ricciardi C., Iaccarino M., Iaccarino S., Freda M., et al. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol. Ther 2011, 12(5):447-457.
8. Taby R., Issa J.P. Cancer epigenetics. CA Cancer J. Clin 2010, 60(6):376-392.
9. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med 2011, 17(3):330-339.
10. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol 2007, 40(2):142-150.
11. Ramachandran K., Singal R. DNA methylation and field cancerization. Epigenomics 2012, 4(3):243-245.
12. Ushijima T. Epigenetic field for cancerization: its cause and clinical implications. BMC Proc 2013, 7(Suppl. 2):K22.
13. Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol. Biomarkers Prev 2006, 15(11):2317-2321.
14. Partridge M., Pateromichelakis S., Phillips E., Emilion G.G., A'Hern R.P., Langdon J.D. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000, 60(14):3893-3898.
15. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60(18):5021-5026.
16. Nakajima T., Enomoto S., Ushijima T. DNA methylation: a marker for carcinogen exposure and cancer risk. Environ. Health Prev. Med 2008, 13(1):8-15.
17. Fang M., Hutchinson L., Deng A., Green M.R. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proc. Natl. Acad. Sci. U.S.A. 2016, 113(5):1250-1255.
18. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009, 1(2):239-259.
19. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., et al. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300(5618):489-492.
20. Cordaux R., Batzer M.A. The impact of retrotransposons on human genome evolution. Nat. Rev. Genet 2009, 10(10):691-703.
21. Enzinger P.C., Mayer R.J. Esophageal cancer. N. Engl. J. Med 2003, 349(23):2241-2252.
22. Agarwal A., Polineni R., Hussein Z., Vigoda I., Bhagat T.D., Bhattacharyya S., et al. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int. J. Clin. Exp. Pathol 2012, 5(5):382-396.
23. Eads C.A., Lord R.V., Wickramasinghe K., Long T.I., Kurumboor S.K., Bernstein L., et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001, 61(8):3410-3418.
24. Jin Z., Hamilton J.P., Yang J., Mori Y., Olaru A., Sato F., et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol. Biomarkers Prev 2008, 17(1):111-117.
25. Clement G., Bosman F.T., Fontolliet C., Benhattar J. Monoallelic methylation of the APC promoter is altered in normal gastric mucosa associated with neoplastic lesions. Cancer Res 2004, 64(19):6867-6873.
26. Clement G., Braunschweig R., Pasquier N., Bosman F.T., Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J. Pathol 2006, 208(1):100-107.
27. Wang J.S., Guo M., Montgomery E.A., Thompson R.E., Cosby H., Hicks L., et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am. J. Gastroenterol 2009, 104(9):2153-2160.
28. Jin Z., Cheng Y., Olaru A., Kan T., Yang J., Paun B., et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int. J. Cancer 2008, 123(10):2331-2336.
29. Lee O.J., Schneider-Stock R., McChesney P.A., Kuester D., Roessner A., Vieth M., et al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 2005, 7(9):854-861.
30. Kuester D., El-Rifai W., Peng D., Ruemmele P., Kroeckel I., Peters B., et al. Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett 2009, 275(1):117-126.
31. Klump B., Hsieh C.J., Holzmann K., Gregor M., Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998, 115(6):1381-1386.
32. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24(25):4138-4148.
33. Jin Z., Cheng Y., Gu W., Zheng Y., Sato F., Mori Y., et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009, 69(10):4112-4115.
34. Smith E., De Young N.J., Pavey S.J., Hayward N.K., Nancarrow D.J., Whiteman D.C., et al. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol. Cancer 2008, 7:75.
35. Jin Z., Olaru A., Yang J., Sato F., Cheng Y., Kan T., et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin. Cancer Res 2007, 13(21):6293-6300.
36. Kuester D., Dar A.A., Moskaluk C.C., Krueger S., Meyer F., Hartig R., et al. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia 2007, 9(3):236-245.
37. Peng D.F., Razvi M., Chen H., Washington K., Roessner A., Schneider-Stock R., et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 2009, 58(1):5-15.
38. Ishii T., Murakami J., Notohara K., Cullings H.M., Sasamoto H., Kambara T., et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007, 56(1):13-19.
39. Tanaka F., Yamamoto K., Suzuki S., Inoue H., Tsurumaru M., Kajiyama Y., et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 2010, 59(11):1457-1464.
40. Steevens J., Schouten L.J., Goldbohm R.A., van den Brandt P.A. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut 2010, 59(1):39-48.
41. Oka D., Yamashita S., Tomioka T., Nakanishi Y., Kato H., Kaminishi M., et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 2009, 115(15):3412-3426.
42. Baba Y., Murata A., Watanabe M., Baba H. Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer. Surg. Today 2014, 44(10):1807-1816.
43. Shigaki H., Baba Y., Watanabe M., Iwagami S., Miyake K., Ishimoto T., et al. LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann. Surg. Oncol 2012, 19(13):4238-4243.
44. Matsuda Y., Yamashita S., Lee Y.C., Niwa T., Yoshida T., Gyobu K., et al. Hypomethylation of Alu repetitive elements in esophageal mucosa, and its potential contribution to the epigenetic field for cancerization. Cancer Causes Control 2012, 23(6):865-873.
45. Park S.Y., Yoo E.J., Cho N.Y., Kim N., Kang G.H. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J. Pathol 2009, 219(4):410-416.
46. Bae J.M., Shin S.H., Kwon H.J., Park S.Y., Kook M.C., Kim Y.W., et al. ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications. Int. J. Cancer 2012, 131(6):1323-1331.
47. Kosumi K., Baba Y., Ishimoto T., Harada K., Miyake K., Izumi D., et al. Relationship between LINE-1 hypomethylation and Helicobacter pylori infection in gastric mucosae. Med. Oncol 2015, 32(4):117.
48. Yamamoto E., Toyota M., Suzuki H., Kondo Y., Sanomura T., Murayama Y., et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol. Biomarkers Prev 2008, 17(10):2555-2564.
49. Kamiyama H., Suzuki K., Maeda T., Koizumi K., Miyaki Y., Okada S., et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012, 31(48):5029-5037.
50. Liu J., Hesson L.B., Meagher A.P., Bourke M.J., Hawkins N.J., Rand K.N., et al. Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa. Cancer Prev. Res. (Phila) 2012, 5(7):921-929.
51. Correa P. Bacterial infections as a cause of cancer. J. Natl Cancer Inst 2003, 95(7):E3.
52. Correa P. Helicobacter pylori infection and gastric cancer. Cancer Epidemiol. Biomarkers Prev 2003, 12(3):238s-241s.
53. Szaleczky E., Pronai L., Molnar B., Berczi L., Feher J., Tulassay Z. Increased cell proliferation in chronic Helicobacter pylori positive gastritis and gastric carcinoma - correlation between immuno-histochemistry and Tv image cytometry. Anal. Cell. Pathol 2000, 20(2-3):131-139.
54. Chan A.O., Lam S.K., Wong B.C., Wong W.M., Yuen M.F., Yeung Y.H., et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52(4):502-506.
55. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res 2006, 12(3 Pt 1):989-995.
56. Yoshida S., Yamashita S., Niwa T., Mori A., Ito S., Ichinose M., et al. Epigenetic inactivation of FAT4 contributes to gastric field cancerization. Gastric Cancer 2016.
57. Miyazaki T., Murayama Y., Shinomura Y., Yamamoto T., Watabe K., Tsutsui S., et al. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter 2007, 12(5):523-531.
58. Nakajima T., Enomoto S., Yamashita S., Ando T., Nakanishi Y., Nakazawa K., et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J. Gastroenterol 2010, 45(1):37-44.
59. Vitkute J., Stankevicius K., Tamulaitiene G., Maneliene Z., Timinskas A., Berg D.E., et al. Specificities of eleven different DNA methyltransferases of Helicobacter pylori strain 26695. J. Bacteriol 2001, 183(2):443-450.
60. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001, 61(9):3573-3577.
61. Ushijima T., Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin. Cancer Res 2012, 18(4):923-929.
62. Hur K., Niwa T., Toyoda T., Tsukamoto T., Tatematsu M., Yang H.K., et al. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis 2011, 32(1):35-41.
63. Leodolter A., Alonso S., Gonzalez B., Ebert M.P., Vieth M., Rocken C., et al. Somatic DNA hypomethylation in H. pylori-associated high-risk gastritis and gastric cancer: enhanced somatic hypomethylation associates with advanced stage cancer. Clin. Transl. Gastroenterol 2015, 6:e85.
64. Kim J.S., Chung W.C., Lee K.M., Paik C.N., Lee K.S., Kim H.J., et al. Association between genetic instability and Helicobacter pylori infection in gastric epithelial dysplasia. Gastroenterol. Res. Pract 2012, 2012:360929.
65. Nanjo S., Asada K., Yamashita S., Nakajima T., Nakazawa K., Maekita T., et al. Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer 2012, 15(4):382-388.
66. Asada K., Nakajima T., Shimazu T., Yamamichi N., Maekita T., Yokoi C., et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut 2015, 64(3):388-396.
67. Woo H.D., Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS ONE 2012, 7(4):e34615.
68. Gao Y., Baccarelli A., Shu X.O., Ji B.T., Yu K., Tarantini L., et al. Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br. J. Cancer 2012, 106(3):585-591.
69. Hou L., Wang H., Sartori S., Gawron A., Lissowska J., Bollati V., et al. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int. J. Cancer 2010, 127(8):1866-1874.
70. Takeshima H., Niwa T., Takahashi T., Wakabayashi M., Yamashita S., Ando T., et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett 2015, 357(1):328-338.
71. Van Assche G., Dignass A., Bokemeyer B., Danese S., Gionchetti P., Moser G., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J. Crohns Colitis 2013, 7(1):1-33.
72. Hsieh C.J., Klump B., Holzmann K., Borchard F., Gregor M., Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 1998, 58(17):3942-3945.
73. Sato F., Harpaz N., Shibata D., Xu Y., Yin J., Mori Y., et al. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 2002, 62(4):1148-1151.
74. Fujii S., Tominaga K., Kitajima K., Takeda J., Kusaka T., Fujita M., et al. Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut 2005, 54(9):1287-1292.
75. Tahara T., Shibata T., Nakamura M., Okubo M., Yamashita H., Yoshioka D., et al. Host genetic factors, related to inflammatory response, influence the CpG island methylation status in colonic mucosa in ulcerative colitis. Anticancer Res 2011, 31(3):933-938.
76. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med 2009, 361(25):2449-2460.
77. Rashid A., Shen L., Morris J.S., Issa J.P., Hamilton S.R. CpG island methylation in colorectal adenomas. Am. J. Pathol 2001, 159(3):1129-1135.
78. Li H., Myeroff L., Smiraglia D., Romero M.F., Pretlow T.P., Kasturi L., et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(14):8412-8417.
79. Chan A.O., Broaddus R.R., Houlihan P.S., Issa J.P., Hamilton S.R., Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am. J. Pathol 2002, 160(5):1823-1830.
80. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(15):8681-8686.
81. Worthley D.L., Whitehall V.L., Buttenshaw R.L., Irahara N., Greco S.A., Ramsnes I., et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010, 29(11):1653-1662.
82. Luo Y., Yu M., Grady W.M. Field cancerization in the colon: a role for aberrant DNA methylation?. Gastroenterol. Rep. (Oxf) 2014, 2(1):16-20.
83. Belshaw N.J., Elliott G.O., Foxall R.J., Dainty J.R., Pal N., Coupe A., et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br. J. Cancer 2008, 99(1):136-142.
84. Belshaw N.J., Pal N., Tapp H.S., Dainty J.R., Lewis M.P., Williams M.R., et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis 2010, 31(6):1158-1163.
85. Alonso S., Dai Y., Yamashita K., Horiuchi S., Dai T., Matsunaga A., et al. Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget 2015, 6(5):3420-3431.
86. Figueiredo J.C., Grau M.V., Wallace K., Levine A.J., Shen L., Hamdan R., et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol. Biomarkers Prev 2009, 18(4):1041-1049.
87. Iacopetta B., Grieu F., Phillips M., Ruszkiewicz A., Moore J., Minamoto T., et al. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci 2007, 98(9):1454-1460.
88. Takeshima H., Ikegami D., Wakabayashi M., Niwa T., Kim Y.J., Ushijima T. Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells. Carcinogenesis 2012, 33(12):2384-2390.